Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2022 Mar 7;126(9):1362. doi: 10.1038/s41416-022-01772-z

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Jesper van Breeschoten 1,2, Michel W J M Wouters 1,3, Doranne L Hilarius 4, John B Haanen 5, Christian U Blank 5,6, Maureen J B Aarts 7, Franchette W P J van den Berkmortel 8, Jan-Willem B de Groot 9, Geke A P Hospers 10, Ellen Kapiteijn 11, Djura Piersma 12, Roos S van Rijn 13, Karijn P M Suijkerbuijk 14, Willeke A M Blokx 15, Bert-Jan J ten Tije 16, Astrid A M van der Veldt 17, Art Vreugdenhil 18, Marye J Boers-Sonderen 19, Alfonsus J M van den Eertwegh 2,✉
PMCID: PMC9043178  PMID: 35256756

Correction to: British Journal of Cancer 10.1038/s41416-020-01229-1, published online 26 January 2021

The original version of this article unfortunately contained a mistake. During online publication of this article an incorrect notification was included by the Publisher in the Additional Information. The notification incorrectly stated that the licence terms for these articles would switch to a Creative Commons Attribution 4.0 International (CC BY 4.0) after a period of 12 months. This notification has been removed and the articles have been updated.

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES